Bruker (BRKR) to Release Quarterly Earnings on Tuesday

Bruker (NASDAQ:BRKR) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Bruker to post earnings of $0.3848 per share and revenue of $853.5740 million for the quarter. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:00 AM ET.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million during the quarter, compared to analyst estimates of $795.62 million. During the same period in the previous year, the company posted $0.47 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, analysts expect Bruker to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bruker Stock Down 2.3%

BRKR stock opened at $62.84 on Friday. Bruker has a twelve month low of $28.53 and a twelve month high of $65.30. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The stock’s 50 day moving average is $58.15 and its 200-day moving average is $46.66. The firm has a market capitalization of $9.57 billion, a PE ratio of -261.83, a P/E/G ratio of 2.01 and a beta of 1.29.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were issued a dividend of $0.05 per share. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a yield of 0.3%. Bruker’s payout ratio is -83.33%.

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently modified their holdings of the business. Allworth Financial LP raised its stake in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the period. Federated Hermes Inc. boosted its stake in Bruker by 6.7% in the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after purchasing an additional 380 shares during the period. Parallel Advisors LLC boosted its stake in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the period. Los Angeles Capital Management LLC purchased a new position in Bruker during the 4th quarter valued at about $26,000. Finally, UMB Bank n.a. increased its position in shares of Bruker by 57.9% during the fourth quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock valued at $74,000 after buying an additional 576 shares during the period. Institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

BRKR has been the topic of several research analyst reports. TD Cowen reissued a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. UBS Group set a $60.00 target price on Bruker in a research note on Wednesday, June 24th. Barclays boosted their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Citigroup increased their price target on shares of Bruker from $44.00 to $60.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, Guggenheim raised their price objective on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $56.79.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.